Ionis DAWNZERA EU Approval Triggers $15M Milestone, Royalties
Event summary
- Ionis Pharmaceuticals’ DAWNZERA (donidalorsen) received EU approval for HAE prophylaxis in adults and adolescents (12+).
- The approval is based on positive Phase 3 OASIS-HAE and OASISplus study data, demonstrating a 94% mean monthly attack rate reduction at one year.
- DAWNZERA is administered via subcutaneous autoinjector every 4-8 weeks.
- Ionis is eligible for a $15 million milestone payment and tiered royalties (up to 30%) on net product sales.
- The drug was previously approved by the U.S. FDA in August 2025.
The big picture
The approval of DAWNZERA represents a significant win for Ionis, validating its RNA-targeting technology and expanding its presence in the rare disease market. HAE affects approximately 1 in 50,000 people globally, creating a niche but potentially lucrative market. The partnership with Otsuka provides Ionis with a well-established commercial infrastructure for European distribution, but also means Ionis’s revenue is dependent on Otsuka’s execution.
What we're watching
- Commercialization
- The speed of DAWNZERA’s rollout across EU markets will be critical, given the drug’s self-administered nature and the need for patient education and access programs.
- Competitive Landscape
- While currently the only RNA-targeted therapy for HAE, the emergence of alternative prophylactic treatments could erode DAWNZERA’s market share over time.
- Royalty Impact
- Ionis’s royalty revenue stream will be directly tied to Otsuka’s sales performance, making the partnership’s commercial execution a key factor in Ionis’s financial outlook.
Related topics